Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza challenge

Vaccine

Volumn 27, Issue 4, 2009, Pages 530-541

  Haynes, Joel R ^a   Dokken, Leslie ^a   Wiley, James A ^b   Cawthon, Andrew G ^c   Bigger, John ^c   Harmsen, Allen G ^b   Richardson, Charles ^a  

^a LigoCyte Pharmaceuticals Inc   (United States)

^b MONTANA STATE UNIVERSITY   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Influenza; Vaccine; Virus like particles

Indexed keywords

AVIAN INFLUENZA VACCINE; GAG PROTEIN; VIRUS HEMAGGLUTININ;

ANIMAL EXPERIMENT; ARTICLE; AVIAN INFLUENZA; BACULOVIRUS; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; FEMALE; FERRET; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; MORBIDITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; SUCROSE GRADIENT; UPPER RESPIRATORY TRACT; VIRUS DETECTION; VIRUS HEMAGGLUTINATION; VIRUS LIKE AGENT; VIRUS TYPING;

ANIMALS; BACULOVIRIDAE; CELLS, CULTURED; FEMALE; FERRETS; GENE PRODUCTS, GAG; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MALE; MICE; MICE, INBRED BALB C; NEURAMINIDASE; ORTHOMYXOVIRIDAE INFECTIONS; TIME FACTORS; VIRION;

EID: 57749205392     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.11.011     Document Type: Article

References (54)

1. Carrat F., and Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 25 39-40 (2007) 6852-6862
2. Subbarao K., Murphy B.R., and Fauci A.S. Development of effective vaccines against pandemic influenza. Immunity 24 1 (2006) 5-9
3. Subbarao K., and Joseph T. Scientific barriers to developing vaccines against avian influenza viruses. Nat Rev Immunol 7 4 (2007) 267-278
4. Subbarao K., and Luke C. H5N1 viruses and vaccines. PLoS Pathog 3 3 (2007) e40
5. Webster R.G., and Govorkova E.A. H5N1 influenza-continuing evolution and spread. N Engl J Med 355 21 (2006) 2174-2177
6. Doherty P.C., Turner S.J., Webby R.G., and Thomas P.G. Influenza and the challenge for immunology. Nat Immunol 7 5 (2006) 449-455
7. de Jong M.D., Bach V.C., Phan T.Q., Vo M.H., Tran T.T., Nguyen B.H., et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med 352 7 (2005) 686-691
8. Tran T.H., Nguyen T.L., Nguyen T.D., Luong T.S., Pham P.M., Nguyen V.C., et al. Avian influenza A (H5N1) in 10 patients in Vietnam. N Engl J Med 350 12 (2004) 1179-1188
9. Uiprasertkul M., Kitphati R., Puthavathana P., Kriwong R., Kongchanagul A., Ungchusak K., et al. Apoptosis and pathogenesis of avian influenza A (H5N1) virus in humans. Emerg Infect Dis 13 5 (2007) 708-712
10. Ungchusak K., Auewarakul P., Dowell S.F., Kitphati R., Auwanit W., Puthavathana P., et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med 352 4 (2005) 333-340
11. Maassab H.F., and Bryant M.L. The development of live attenuated cold-adapted influenza virus vaccine for humans. Rev Med Virol 9 4 (1999) 237-244
12. Jin H., Lu B., Zhou H., Ma C., Zhao J., Yang C.F., et al. Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. Virology 306 1 (2003) 18-24
13. Cha T.A., Kao K., Zhao J., Fast P.E., Mendelman P.M., and Arvin A. Genotypic stability of cold-adapted influenza virus vaccine in an efficacy clinical trial. J Clin Microbiol 38 2 (2000) 839-845
14. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 356 7 (2007) 685-696
15. Gomez-Puertas P., Albo C., Perez-Pastrana E., Vivo A., and Portela A. Influenza virus matrix protein is the major driving force in virus budding. J Virol 74 24 (2000) 11538-11547
16. Galarza J.M., Latham T., and Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 18 1 (2005) 244-251
17. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., and Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 23 50 (2005) 5751-5759
18. Pushko P., Tumpey T.M., Van Hoeven N., Belser J.A., Robinson R., Nathan M., et al. Evaluation of influenza virus-like particles and Novasome adjuvant as candidate vaccine for avian influenza. Vaccine 25 21 (2007) 4283-4290
19. Quan F.S., Huang C., Compans R.W., and Kang S.M. Virus-like particle vaccine induces protective immunity against homologous and heterologous strains of influenza virus. J Virol 81 7 (2007) 3514-3524
20. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., et al. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 25 19 (2007) 3871-3878
21. Bright R.A., Carter D.M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., et al. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS ONE 3 1 (2008) e1501
22. Matassov D., Cupo A., and Galarza J.M. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol 20 3 (2007) 441-452
23. Quan F.S., Steinhauer D., Huang C., Ross T.M., Compans R.W., and Kang S.M. A bivalent influenza VLP vaccine confers complete inhibition of virus replication in lungs. Vaccine 26 26 (2008) 3352-3361
24. Chen B.J., Leser G.P., Morita E., and Lamb R.A. Influenza virus hemagglutinin and neuraminidase, but not the matrix protein, are required for assembly and budding of plasmid-derived virus-like particles. J Virol 81 13 (2007) 7111-7123
25. Demirov D.G., and Freed E.O. Retrovirus budding. Virus Res 106 2 (2004) 87-102
26. Gheysen D., Jacobs E., de Foresta F., Thiriart C., Francotte M., Thines D., et al. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 59 1 (1989) 103-112
27. Haffar O., Garrigues J., Travis B., Moran P., Zarling J., and Hu S.L. Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system. J Virol 64 6 (1990) 2653-2659
28. Haynes J.R., Cao S.X., Rovinski B., Sia C., James O., Dekaban G.A., et al. Production of immunogenic HIV-1 viruslike particles in stably engineered monkey cell lines. AIDS Res Hum Retrovir 7 1 (1991) 17-27
29. Karacostas V., Nagashima K., Gonda M.A., and Moss B. Human immunodeficiency virus-like particles produced by a vaccinia virus expression vector. Proc Natl Acad Sci U S A 86 22 (1989) 8964-8967
30. Rovinski B., Haynes J.R., Cao S.X., James O., Sia C., Zolla-Pazner S., et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J Virol 66 7 (1992) 4003-4012
31. Rein A., McClure M.R., Rice N.R., Luftig R.B., and Schultz A.M. Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc Natl Acad Sci U S A 83 19 (1986) 7246-7250
32. Schultz A.M., and Rein A. Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events. J Virol 63 5 (1989) 2370-2373
33. Yu Z., Beer C., Koester M., and Wirth M. Caveolin-1 interacts with the Gag precursor of murine leukaemia virus and modulates virus production. Virol J 3 (2006) 73
34. Takeda M., Leser G.P., Russell C.J., and Lamb R.A. Influenza virus hemagglutinin concentrates in lipid raft microdomains for efficient viral fusion. Proc Natl Acad Sci U S A 100 25 (2003) 14610-14617
35. Scheiffele P., Roth M.G., and Simons K. Interaction of influenza virus haemagglutinin with sphingolipid-cholesterol membrane domains via its transmembrane domain. EMBO J 16 18 (1997) 5501-5508
36. Barman S., Adhikary L., Chakrabarti A.K., Bernas C., Kawaoka Y., and Nayak D.P. Role of transmembrane domain and cytoplasmic tail amino acid sequences of influenza a virus neuraminidase in raft association and virus budding. J Virol 78 10 (2004) 5258-5269
37. Barman S., and Nayak D.P. Analysis of the transmembrane domain of influenza virus neuraminidase, a type II transmembrane glycoprotein, for apical sorting and raft association. J Virol 74 14 (2000) 6538-6545
38. Guo L., Lu X., Kang S.M., Chen C., Compans R.W., and Yao Q. Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles. Virology 313 2 (2003) 502-513
39. Szecsi J., Boson B., Johnsson P., Dupeyrot-Lacas P., Matrosovich M., Klenk H.D., et al. Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol J 3 (2006) 70
40. Guide for the care and use of laboratory animals. http://wwwnapedu/readingroom/books/labrats/.
41. WHO manual on animal influenza diagnosis and surveillance. http://wwwwhoint/vaccine_research/diseases/influenza/WHO_manual_on_animal-diagnosis_and_surveillance_2002_5pdf.
42. Hamilton M.A., Russo R.C., and Thurston R.V. Trimmed Spearman-Karber method for estimating median lethal concentrations in toxicity bioassays. Environ Sci Technol 11 7 (1977) 714-719
43. Stephenson I., Wood J.M., Nicholson K.G., Charlett A., and Zambon M.C. Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine. Virus Res 103 1-2 (2004) 91-95
44. Govorkova E.A., Rehg J.E., Krauss S., Yen H.L., Guan Y., Peiris M., et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J Virol 79 4 (2005) 2191-2198
45. Govorkova E.A., Webby R.J., Humberd J., Seiler J.P., and Webster R.G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 194 2 (2006) 159-167
46. Abe T., Hemmi H., Miyamoto H., Moriishi K., Tamura S., Takaku H., et al. Involvement of the Toll-like receptor 9 signaling pathway in the induction of innate immunity by baculovirus. J Virol 79 5 (2005) 2847-2858
47. Abe T., Takahashi H., Hamazaki H., Miyano-Kurosaki N., Matsuura Y., and Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 171 3 (2003) 1133-1139
48. Gronowski A.M., Hilbert D.M., Sheehan K.C., Garotta G., and Schreiber R.D. Baculovirus stimulates antiviral effects in mammalian cells. J Virol 73 12 (1999) 9944-9951
49. Zhang S.X., Han Y., and Blissard G.W. Palmitoylation of the Autographa californica multicapsid nucleopolyhedrovirus envelope glycoprotein GP64: mapping, functional studies, and lipid rafts. J Virol 77 11 (2003) 6265-6273
50. Hoffmann E., Lipatov A.S., Webby R.J., Govorkova E.A., and Webster R.G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A 102 36 (2005) 12915-12920
51. Baras B., Stittelaar K.J., Simon J.H., Thoolen R.J., Mossman S.P., Pistoor F.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS ONE 3 1 (2008) e1401
52. Sandbulte M.R., Jimenez G.S., Boon A.C., Smith L.R., Treanor J.J., and Webby R.J. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4 2 (2007) e59
53. Gillim-Ross L., and Subbarao K. Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses?. PLoS Med 4 2 (2007) e91
54. Oomens A.G., and Blissard G.W. Requirement for GP64 to drive efficient budding of Autographa californica multicapsid nucleopolyhedrovirus. Virology 254 2 (1999) 297-314